prohibited substance comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Arrived in Europe in the 16th century, this solanaceous plant (with a pink skinned tuber in England and a yellow skin in Spain) spread in the Principality of Liege, Ireland, Flanders, Germany, Switzerland, Italy, Austria, etc. In France, its resemblance with toxic species (for example the daturas, known for their toxicity to livestock, but also to humans) and the lack of techniques of conservation and use, are brakes to its cultivation, beside purely agronomic reasons (bad ecological adaptation) or religious (non-perception of the tithe on this food). In the Théâtre d'agriculture et Mesnage des champs, published in 1600, Olivier de Serres already recommended the cultivation of the "white truffle" or "cartoufle" and found it to have a flavor worthy of the best black truffles. Around 1750, the cultivation and consumption of tubers were recommended by several people or institutions: Duhamel du Monceau, the bishops of Albi and Léon, the minister Turgot, Rose Bertin, the Agricultural Society of Rennes. Ten years before the publications of Antoine Parmentier and Samuel Engel, Duhamel du Monceau "strongly exhorts farmers not to neglect the cultivation of this plant" and remarks that "it is an excellent food especially with a little bacon and salted pork". But the French population remains more than reticent before this dish: the majority of French people still disdain it as a food for humans, even if it is cultivated and used in some regions.
== Properties of organisms containing recombinant DNA == In most cases, organisms containing recombinant DNA have apparently normal phenotypes. That is, their appearance, behavior and metabolism are usually unchanged, and the only way to demonstrate the presence of recombinant sequences is to examine the DNA itself, typically using a polymerase chain reaction (PCR) test. Significant exceptions exist, and are discussed below. If the rDNA sequences encode a gene that is expressed, then the presence of RNA and/or protein products of the recombinant gene can be detected, typically using RT-PCR or western hybridization methods. Gross phenotypic changes are not the norm, unless the recombinant gene has been chosen and modified so as to generate biological activity in the host organism. Additional phenotypes that are encountered include toxicity to the host organism induced by the recombinant gene product, especially if it is over-expressed or expressed within inappropriate cells or tissues. In some cases, recombinant DNA can have deleterious effects even if it is not expressed. One mechanism by which this happens is insertional inactivation, in which the rDNA becomes inserted into a host cell's gene. In some cases, researchers use this phenomenon to "knock out" genes to determine their biological function and importance. Another mechanism by which rDNA insertion into chromosomal DNA can affect gene expression is by inappropriate activation of previously unexpressed host cell genes.
=== Reducing end === Disaccharides consist of two monosaccharides and may be either reducing or nonreducing. Even a reducing disaccharide will only have one reducing end, as disaccharides are held together by glycosidic bonds, which consist of at least one anomeric carbon. With one anomeric carbon unable to convert to the open-chain form, only the free anomeric carbon is available to reduce another compound, and it is called the reducing end of the disaccharide. A nonreducing disaccharide is that which has both anomeric carbons tied up in the glycosidic bond. Similarly, most polysaccharides have only one reducing end.
=== Research environment === In the United States, research in digital agriculture is primarily funded by the National Institute of Food and Agriculture (NIFA) which comes under the US Department of Agriculture and to a lesser extent, by the National Science Foundation. Two large institutes applying IoT or artificial intelligence in digital agriculture have been unveiled by these funding organizations working together.
Sources: en.wikipedia.org
== Climate change == Climate change exacerbates threats to aquatic plants through rising temperatures, altered precipitation patterns, and increased frequency of extreme weather events. Warmer temperatures can favor invasive species that outcompete native plants. For example, studies predict that the ranges of invasive species like Egeria densa and Myriophyllum aquaticum may expand significantly by 2070 due to climate change. Additionally, earlier spring warming allows invasive species to establish before native plants, giving them a competitive advantage. Climate-induced changes also affect water levels and flow regimes, impacting aquatic plant distribution and health. Droughts can reduce water availability, while intense storms can lead to increased runoff and sedimentation, both detrimental to aquatic vegetation.
cassette A pre-existing nucleic acid sequence or construct, especially a DNA vector with an annotated sequence and precisely positioned regulatory elements, into which one or more fragments can be readily inserted or recombined by various genetic engineering methods. Recombinant plasmid vectors containing reliable promoters, origins of replication, and antibiotic resistance genes are commercially manufactured as cassettes to allow scientists to easily swap genes of interest into and out of an active "slot" or locus within the plasmid. See also multiple cloning site.
=== Spontaneous mutation === Spontaneous mutations occur with non-zero probability even given a healthy, uncontaminated cell. Naturally occurring oxidative DNA damage is estimated to occur 10,000 times per cell per day in humans and 100,000 times per cell per day in rats. Spontaneous mutations can be characterized by the specific change:
== S == Secondary ion mass spectrometry Supercritical fluid chromatography (SFC) Scanning transmission electron microscopy (STEM) Scanning tunneling microscope (STM) Scanning electron microscope (SEM)
The TSH receptor is found mainly on thyroid follicular cells. Stimulation of the receptor increases T3 and T4 production and secretion. This occurs through stimulation of six steps in thyroid hormone synthesis: (1) Up-regulating the activity of the sodium-iodide symporter (NIS) on the basolateral membrane of thyroid follicular cells, thereby increasing intracellular concentrations of iodine (iodine trapping). (2) Stimulating iodination of thyroglobulin in the follicular lumen, a precursor protein of thyroid hormone. (3) Stimulating the conjugation of iodinated tyrosine residues. This leads to the formation of thyroxine (T4) and triiodothyronine (T3) that remain attached to the thyroglobulin protein. (4) Increased endocytosis of the iodinated thyroglobulin protein across the apical membrane back into the follicular cell. (5) Stimulation of proteolysis of iodinated thyroglobulin to form free thyroxine (T4) and triiodothyronine (T3). (6) Secretion of thyroxine (T4) and triiodothyronine (T3) across the basolateral membrane of follicular cells to enter the circulation. This occurs by an unknown mechanism. Stimulating antibodies to the TSH receptor mimic TSH and cause Graves' disease. In addition, hCG shows some cross-reactivity to the TSH receptor and therefore can stimulate production of thyroid hormones. In pregnancy, prolonged high concentrations of hCG can produce a transient condition termed gestational hyperthyroidism. This is also the mechanism of trophoblastic tumors increasing the production of thyroid hormones.
Sources: en.wikipedia.org
From the late 1960s to the early 1970s, with the rapid surge in recreational drug use in the U.S., the production of narcotics in Mexico, particularly marijuana, expanded exponentially, and Mexican criminals started to smuggle drugs on a major scale. During the 1960s and 1970s, Mexico participated in a series of U.S.-backed anti-narcotics initiatives, including Operation Intercept and Operation Condor. These operations were formally justified on the grounds of combating the cultivation of opium poppies and marijuana in Mexico's so-called "Golden Triangle" region, an area encompassing parts of the states of Sinaloa, Durango, and Chihuahua. As part of the campaign, the Mexican government deployed about 10,000 soldiers and police. The operation resulted in mass arrests, torture, and imprisonment of peasants who were often accused of aiding leftist insurgency groups, but no major traffickers were captured. Contemporary assessments deemed the initiatives a failure, citing their inability to curb narcotics production, enabling military corruption, and their record of human rights abuses in rural areas. As U.S. efforts in the war on drugs intensified, crackdowns in Florida and the Caribbean during the Miami drug war forced Colombian traffickers to develop new routes for smuggling cocaine into the United States. By the early 1980s, the Medellin Cartel and Cali Cartel oversaw production, while distribution increasingly relied on Mexican traffickers.
Leonidas Zervas (Greek: Λεωνίδας Ζέρβας, pronounced [leoˈniðas ˈzervas]; 21 May 1902 – 10 July 1980) was a Greek organic chemist who made seminal contributions in peptide chemical synthesis. Together with his mentor Max Bergmann they laid the foundations for the field in 1932 with their major discovery, the Bergmann-Zervas carboxybenzoxy oligopeptide synthesis which remained unsurpassed in utility for the next two decades. The carboxybenzyl protecting group he discovered is often abbreviated Z in his honour. Throughout his life Zervas also served in many important posts, including President of the Academy of Athens or briefly Minister of Industry of Greece. He received numerous awards and honours during his life and posthumously, such as Foreign Member of the USSR Academy of Sciences or the first Max Bergmann golden medal.
== Future Applications == Reticular cells were once considered passive structural elements. However, they are now being recognized as potential regulators of immune function. Their influence extends from organizing lymphoid tissue to now even directing immune responses and contributing to tumor regulation. As researchers continue to uncover the complexity of these cells, new technologies such as single-cell RNA sequencing are being used to provide more insight into their genetic diversity and viability in the body. Future studies will likely focus on manipulating these cells to improve immune therapies, including against tumors which could be extremely beneficial in the world of medicine.. By mapping how each subtype interacts with immune cells and signaling molecules in the body, scientists may be able to utilize reticular cells to enhance vaccine responses and accelerate wound healing. Lütge, Pikor, and Ludewig (2021) emphasize that understanding the cellular differences of different reticular cell subtypes will be critical for developing targeted treatments that alter the immune system safely and effectively. In conclusion, reticular cells occupy many unique positions in tissue structure and offer the human body immune regulation. Continued exploration of their biological structure and interactions will not only deepen our understanding of the immune system but may also alter how clinicians approach diseases that involve immune system irregularities.
== Function == This gene encodes one of the two alpha chains of type XI collagen, a minor fibrillar collagen. It is located on chromosome 6 very close to but separate from the gene for retinoid X receptor beta. Type XI collagen is a heterotrimer but the third alpha chain is a post-translationally modified alpha 1 type II chain. Proteolytic processing of this type XI chain produces PARP, a proline/arginine-rich protein that is an amino terminal domain. Mutations in this gene are associated with type III Stickler syndrome, otospondylomegaepiphyseal dysplasia (OSMED syndrome), Weissenbacher-Zweymuller syndrome, and autosomal dominant nonsyndromic sensorineural 13 deafness. Three transcript variants encoding different isoforms have been identified for this gene.
Chondrocytes Cells that produce the cartilage matrix and maintain the extracellular matrix. Help to increase flexibility in cartilage, and help to maintain homeostasis in articular cartilage. Chondrocytes are specialized cells, while chondronectins are proteins that are produced by chondrocytes to mediate attachment of chondrocytes to type II collagen. Chondroitin Sulfate Proteoglycans (CSPGs) Components of the ECM that contain glycosaminoglycan (GAG) side chains, and a protein core. These components help with binding of cells and receptors, as well as cellular growth. Both CSPGs and chondronectins are part of the ECM, but they vary in their roles, as CSPGs focus more on axonal growth and chondronectins focus on adhesion.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.